Abstract:
Objective
To analyze the clinical features and survival of molecular subtyping in breast cancer patients.
Methods
A total of 482 cases of operable breast cancer were analyzed retrospectively.Molecular subtypes,based on immunohistochemistry,were categorized as follows:luminal A [ER(+)or PR(+)/HER-2(-)],luminal B[ER(+)or PR(+)/HER-2(+)],HER-2(+)subtype[ER(-),PR(-)/HER-2(+)],and basal-like subtype[ER(-),PR(-)/HER-2(-)].The clinical features and prognostic status were analyzed.
Results
Among the 482 cases,222 cases(46.1%)were luminal A,71(1.7%)were luminal B,50(10.4%)were HER-2(+)subtype,and 139(28.8%)were basal-like subtype.The molecular subtypes did not differ in age,menopausal status,tumor size,node status and TNM stage.Of the 482 cases,441 had complete follow-up data,the median follow-up time was 62 months,ranging 36-88 months.Distant metastatic rates of HER-2(+)subtype and basal-like subtype were higher than that of luminal A,with statistically significant difference(χ2=11.659,P=0.009).Kaplan-Meier analysis showed DFS,DDFS and OS were the hig-hest for luminal A and were poor for HER-2(+)subtype and basal-like subtype,with statistically significant difference(Log-Rank test,P＜0.050).
Conclusions
Molecular subtyping could provide important information to predict the prognosis of breast cancer and might be the important basis for individual treatment of breast cancer in future.
Key words:
Breast neoplasms,
Molecular subtype,
HER-2,
Prognosis
Zhen-qiang LIAN, Jie-Hua HE, Xi WANG, Jun TANG, Ming-tian YANG. Clinical features and survival analysis of molecular subtyping of breast cancer[J]. Chinese Journal of Breast Disease(Electronic Edition), 2009, 03(02): 139-146.